{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:48:51Z","timestamp":1792028931900,"version":"4.4.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/ftd.0b013e3181dad1fb","type":"journal-article","created":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T04:00:19Z","timestamp":1273636819000},"page":"438-447","source":"Crossref","is-referenced-by-count":165,"title":["Plasma Clozapine, Norclozapine, and the Clozapine:Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993\u20132007"],"prefix":"10.1097","volume":"32","author":[{"given":"Lewis","family":"Couchman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip Edgar","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar Pathrose","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert James","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"S1","key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/hup.917","article-title":"Haematological toxicity of drugs used in psychiatry.","volume":"23","author":"Flanagan","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157488608784529251","article-title":"Side-effects of clozapine and some other psychoactive drugs.","volume":"3","author":"Flanagan","year":"2008","journal-title":"Curr Drug Saf"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0269881107075509","article-title":"Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.","volume":"21","author":"Barnett","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01046700","article-title":"Clinical pharmacokinetics of clozapine in chronic schizophrenic patients.","volume":"34","author":"Cheng","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoking, age, sex and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/FTD.0b013e3181a1c856","article-title":"Therapeutic drug monitoring of clozapine in a hemodialysed smoking patient with schizophrenia.","volume":"31","author":"Jacob","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-2007-1014307","article-title":"Seizures following smoking cessation in a clozapine responder.","volume":"27","author":"McCarthy","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/138920007780655469","article-title":"CYP-mediated clozapine interactions: how predictable are they?","volume":"8","author":"Chetty","year":"2007","journal-title":"Curr Drug Metab"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1176\/appi.psy.48.2.170","article-title":"Clozapine case series.","volume":"48","author":"Sandson","year":"2007","journal-title":"Psychosomatics"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug-drug interactions.","volume":"9","author":"Urichuk","year":"2008","journal-title":"Curr Drug Metab"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","article-title":"ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.","volume":"29","author":"Jaquenoud Sirot","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/0929867043456089","article-title":"Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.","volume":"11","author":"Raggi","year":"2004","journal-title":"Curr Med Chem"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/JCP.0b013e318036bfbb","article-title":"Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis.","volume":"27","author":"Paton","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00044011-200828080-00001","article-title":"Practical issues with amisulpride in the management of patients with schizophrenia.","volume":"28","author":"Pani","year":"2008","journal-title":"Clin Drug Invest"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/bmc.1130090108","article-title":"Measurement of clozapine and norclozapine in plasma\/serum by high performance liquid chromatography with ultraviolet detection.","volume":"9","author":"McCarthy","year":"1995","journal-title":"Biomed Chromatogr"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00007691-200006000-00015","article-title":"Therapeutic drug monitoring of clozapine: an unexpected outcome.","volume":"22","author":"Uges","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.forsciint.2004.10.024","article-title":"Suspected clozapine poisoning in the UK\/Eire, 1992-2003.","volume":"155","author":"Flanagan","year":"2005","journal-title":"Forensic Sci Int"},{"key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1023\/A:1018965622014","article-title":"Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine.","volume":"11","author":"Pokorny","year":"1994","journal-title":"Pharm Res"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.44.12.2247","article-title":"Clozapine-related seizures: experience with 5,629 patients.","volume":"44","author":"Pacia","year":"1994","journal-title":"Neurology"},{"key":"R24-9-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.ftd.0000211801.66569.80","article-title":"Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive\/compulsive symptoms.","volume":"28","author":"Lin","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/10673220216279","article-title":"Optimal dosing of atypical antipsychotics in adults: a review of the current evidence.","volume":"10","author":"Citrome","year":"2002","journal-title":"Harv Rev Psychiatr"},{"key":"R26-9-20210129","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R27-9-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-200106000-00010","article-title":"Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study.","volume":"21","author":"Gaertner","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R28-9-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2006.01.011","article-title":"Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia.","volume":"83","author":"Xiang","year":"2006","journal-title":"Schizophr Res"},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/YIC.0b013e32819f8f17","article-title":"Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration.","volume":"22","author":"Yusufi","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"R30-9-20210129","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/FTD.0b013e31802c052e","article-title":"Therapeutic drug monitoring-based clozapine dosing recommendations.","volume":"29","author":"Zernig","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R31-9-20210129","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.npp.1301279","article-title":"Evaluation of N-desmethylclozapine as a potential antipsychotic-preclinical studies.","volume":"32","author":"Natesan","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"R32-9-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2007.05.004","article-title":"Pharmacology of N-desmethylclozapine.","volume":"115","author":"Lameh","year":"2007","journal-title":"Pharmacol Ther"},{"key":"R33-9-20210129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/WNF.0b013e31818d46f5","article-title":"N-Desmethylclozapine: is there evidence for its antipsychotic potential?","volume":"32","author":"Mendoza","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"R34-9-20210129","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.npp.1301152","article-title":"N-Desmethylclozapine, a major clozapine metabolite, acts as a selective and efficacious delta-opioid agonist at recombinant and native receptors.","volume":"32","author":"Onali","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"R35-9-20210129","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clinbiochem.2008.01.020","article-title":"Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations.","volume":"41","author":"Paz","year":"2008","journal-title":"Clin Biochem"},{"key":"R36-9-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-200205000-00008","article-title":"Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine.","volume":"17","author":"Zullino","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"R37-9-20210129","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.04.003","article-title":"Time response of cytochrome P450 1A2 activity on cessation of heavy smoking.","volume":"76","author":"Faber","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R38-9-20210129","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1176\/appi.psy.49.2.176","article-title":"Clozapine toxicity in smoking cessation and with ciprofloxacin.","volume":"49","author":"Brownlowe","year":"2008","journal-title":"Psychosomatics"},{"key":"R39-9-20210129","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1600-0447.2009.01482.x","article-title":"A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine.","volume":"121","author":"Cormac","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"R40-9-20210129","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-006-0209-9","article-title":"The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.","volume":"62","author":"Haslemo","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"R41-9-20210129","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JCP.0b013e3181acd20b","article-title":"Toxic clozapine serum levels during inflammatory reactions.","volume":"29","author":"Pfuhlmann","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R42-9-20210129","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/clinchem\/39.8.1656","article-title":"Determination of clozapine, norclozapine, and clozapine N-oxide in serum by liquid chromatography.","volume":"39","author":"Volpicelli","year":"1993","journal-title":"Clin Chem"},{"key":"R43-9-20210129","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/00912709922008245","article-title":"Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia.","volume":"39","author":"Guitton","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R44-9-20210129","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0278-5846(01)00291-3","article-title":"Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables.","volume":"26","author":"Palego","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatr"},{"key":"R45-9-20210129","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ps.55.5.491","article-title":"Atypical antipsychotic dosing: the effect of smoking and caffeine.","volume":"55","author":"de Leon","year":"2004","journal-title":"Psychiatr Serv"},{"key":"R46-9-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004591","article-title":"Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables.","volume":"41","author":"Diaz","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"R47-9-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pnpbp.2005.10.008","article-title":"Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients.","volume":"30","author":"Wong","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatr"},{"key":"R48-9-20210129","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0278-5846(03)00148-9","article-title":"Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report.","volume":"27","author":"de Leon","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatr"},{"key":"R49-9-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.psy.43.1.71","article-title":"Death from clozapine-induced constipation: case report and literature review.","volume":"43","author":"Levin","year":"2002","journal-title":"Psychosomatics"},{"key":"R50-9-20210129","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/s-2005-873157","article-title":"Necrotizing enterocolitis after antipsychotic treatment involving clozapine and review of severe digestive complications-a case report.","volume":"38","author":"Khaldi","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"R51-9-20210129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-244X-6-43","article-title":"Case report: rapidly fatal bowel ischaemia on clozapine treatment.","volume":"6","author":"Townsend","year":"2006","journal-title":"BMC Psychiatr"},{"key":"R52-9-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1749-7922-2-21","article-title":"Necrotising colitis related to clozapine? A rare but life threatening side effect.","volume":"2","author":"Leong","year":"2007","journal-title":"World J Emerg Surg"},{"key":"R53-9-20210129","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1136\/emj.2006.042630","article-title":"A case of clozapine-induced paralytic ileus.","volume":"24","author":"Rondla","year":"2007","journal-title":"Emerg Med J"},{"key":"R54-9-20210129","first-page":"144","article-title":"Clozapine-induced intestinal occlusion: a serious side effect.","volume":"78","author":"Pelizza","year":"2007","journal-title":"Acta Biomed"},{"key":"R55-9-20210129","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/10398560701882203","article-title":"Life-threatening constipation associated with clozapine.","volume":"16","author":"Rege","year":"2008","journal-title":"Australas Psychiatr"},{"key":"R56-9-20210129","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4088\/JCP.v69n0509","article-title":"Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases.","volume":"69","author":"Palmer","year":"2008","journal-title":"J Clin Psychiatr"},{"key":"R57-9-20210129","first-page":"30","article-title":"Clozapine-induced bowel infarction: a case report.","volume":"6","author":"McKinnon","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"R58-9-20210129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1176\/appi.psy.50.4.416","article-title":"Fatalities associated with clozapine-related constipation and bowel obstruction: a literature review and two case reports.","volume":"50","author":"Hibbard","year":"2009","journal-title":"Psychosomatics"},{"key":"R59-9-20210129","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/jcp.0b013e31815a257f","article-title":"Clozapine-induced microscopic colitis: a case report and review of the literature.","volume":"27","author":"Pelizza","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R60-9-20210129","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1177\/0091270004266621","article-title":"The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers.","volume":"44","author":"Wang","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R61-9-20210129","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/0044011-200929010-00006","article-title":"Ciprofloxacin strongly inhibits clozapine metabolism: two case reports.","volume":"29","author":"Brouwers","year":"2009","journal-title":"Clin Drug Invest"},{"key":"R62-9-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/FTD.0b013e31815f4e72","article-title":"Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients.","volume":"30","author":"Hermida","year":"2008","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181dad1fb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:23:46Z","timestamp":1786040626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201008000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181dad1fb","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}